By Flavia Fortes and Ilana Kowarski (October 31, 2023) -- Pfizer and Seagen have said antitrust regulators have a lot of questions about whether innovation will be maintained after their deal. But while the companies didn’t indicate which jurisdiction is focused the most on the issue, in the US it would be a difficult theory of harm to prove in court....